

2017 Career Advisory Network (CAN) Schedule & Mentor Bio

Chinese American Bio/Pharmaceutical Society
Business and Development Committee
&
Chinese Biosciences Association

April 29 (Today)	Program Introduction
May 1 – May 25	Online Application
May 26 – June 10	Matching Process
Mid June	1:1 Meeting #1
July	1:1 Meeting #2
August (Time TBD)	CAN Topics Panel Discussion Session
September	1:1 Meeting #3 / Group Activity
October	1:1 Meeting #4
November/December (Time TBD)	Graduation and Mixer/HH

Mentor List/Bio

Michelle Chen, PhD.

1. Educational background: PhD from University of Washington; Postdoc at UCSF; Bioinformatics Training at Stanford
2. Company/current position: Merck, Executive Director, Business Development and Licensing
3. Work experience: 18 years in the industry, mix of R&D, marketing and business development in Rx, Dx and Life Science
4. Interests of the business areas/Specialty in life sciences: Drug discovery and development, oncology, personalized medicine, strategy, innovation
5. Any additional info you would like the mentees to know about you: runner, amateur photographer, mom, traveler, foodie

Ta-Kai Li, Ph.D. is Manager, Drug Safety & Public Health at Gilead Sciences, Inc. Prior to his current role in risk management, Dr. Li worked in safety operations at Gilead, managing case processing and representing drug safety in study management teams for global clinical trials. Before joining Gilead in 2013, Dr. Li was Senior PV Scientist at Janssen Alzheimer Immunotherapy R&D, LLC. Dr. Li started his drug safety career in 2009 at Actelion Pharmaceuticals US, Inc. after completion of the Certificate Program in Clinical Trials Design and Management at University of California Extension, Santa Cruz. He previously held various research positions in biopharmaceutical industry and academia in the San Francisco Bay Area. Dr Li received his B.S. in chemistry from Tamkang University, Taiwan and his Ph.D. in biochemistry from University of Maryland. He completed postdoctoral training at Dana-Farber Cancer Institute/Harvard Medical School and at National Heart, Lung, and Blood Institute, NIH. Dr. Li has been a CBA life-time member since 2009, and he previously served as Director and Secretary in the CBA Board.

Yen-Chi (Laurie) Wu obtained her PhD in Molecular, Cellular, and Developmental Biology (MCDB) program from Indiana University Bloomington, on the study of the microRNAs (miRNAs) pathways during *Drosophila* neural stem cell development. Upon graduation at mid 2014, she joined as postdoctoral fellow at Stanford University by using molecular and genetic approaches to study mechanisms of normal and cancer neural stem cell proliferation and growth in both human and *Drosophila* systems, and her work and interests is to offer novel therapeutic strategies to treat cancers in humans.

Xiaolin (Alan) Hao, Ph.D. is a seasoned medicinal chemist with the passion of discovering innovative medicines to treat diseases with unmet need. He worked on various disease areas including cancer, inflammation, diabetes and obesity in Tularik and Amgen. During his industrial career over the past 15 years, Alan was responsible for providing scientific and technical leadership and strategic direction to the medicinal chemistry projects, and led the medicinal chemistry efforts to move three drug candidates into clinical trials. Most recently, Alan founded AIM Biosciences, with the goal of developing affordable innovative medicines for seriously ill patients. He received his PhD in organic chemistry from the University of Illinois at Chicago and BS from Peking University. He is a member of board of directors at CABS.

Anthony Hsiao, MBA

1. Educational Background: MBA from Columbia Business School
 2. Company: Engagement Manager at BluePrint Research Group
 3. Work Experience: 5+ years life sciences commercial strategy consulting/investing
- Interests/Specialty: Commercial strategy; product launches, forecasting, commercial due diligence.

4. Additional Info: I'm pretty useless on the science and technology side. Happy to work with folks looking to transition or advance in the "business" side of life sciences

Wenyi Chen, PhD, currently works as Field Application Scientist at Nexcelom Bioscience. Nexcelom came to the market with the very first image-based automatic cell counter. Since then, Nexcelom has focused on the technology of image cytometry. The top of the line instrument, Celigo, has been widely used in immuno-oncology, 3D tumorspheroids and drug screening. Wenyi's responsibilities include pre-sale activities: technical presentation and consultation, and on-site demonstration; post-sale activities: instrument training, applications development and troubleshoot. Before joining Nexcelom in 2016, Wenyi was awarded NIH F32 postdoctoral fellowship to conduct his research in the laboratory of Dr. Joseph Wu at Stanford University where he studied the mechanism of cardiac differentiation from human embryonic stem cells (hESCs) and the efficacy of the cell therapy using cardiac cells derived from hESCs. He received his Ph.D. from the Ohio State University and his B.S. from National Taiwan University. Field application scientist can be a very good transition for those academic Ph.D. who want to move away from bench work, to get involved in the business activities and to learn sales skills. Wenyi is happy to share his experience as a Field Application Scientist.

Zhenhai Shen, Ph.D., MBA, is current Director of Alliance Management at Genentech Partnering group. He received his Ph.D. Degree from The Mount Sinai School of Medicine and completed his postdoctoral training at Dana-SFarber Cancer Institute. Zhenhai also holds a MBA degree from Ross School of Business of University of Michigan. Prior to Genentech, Zhenhai worked in Eli Lilly's International Finance group.

Interests of the business areas/Specialty in life sciences: Business support to scientists.

Any additional info you would like the mentees to know about you: Enjoy sharing experiences with younger scientists who are considering business career.

Dr. Aihua Fu is a nanobiotechnologist and an entrepreneur. She is the co-Founder and CEO of NVIGEN Inc., a nanobiotech startup dedicated to developing the best nanoparticles for biological research, diagnostic and therapeutic applications. Magnetic nanoparticles and fluorescent magnetic nanoparticles are among the key products of NVIGEN Inc. These nanoparticle products offer unique advantages for applications such as circulating tumor cell isolation, cfDNA extraction, sequence specific DNA capture, immunodiagnostic assays and T-cell activation and expansion for better Cell therapy. Before she spearheaded the founding of NVIGEN with the support of successful biotechnologists and entrepreneurs, Dr. Fu was trained as a postdoc at Stanford University Center of Cancer Nanotechnology Excellence under the supervision of Prof. Shan X. Wang and Prof. Sam S. Gambhir to engineer nanoparticles with enhanced properties for in vitro diagnostics and in vivo cancer imaging and drug delivery applications. Dr. Fu obtained her Ph.D. from the Chemistry Department of University of California at Berkeley with Prof. Paul Alivisatos, which built a solid foundation for her understanding of the unique properties of nanoparticles and their huge potential in helping define precision disease diagnostics and therapy. Her nanoparticle research and product development efforts were also supported by NIH Pathway to Independence Award and NIH SBIR Awards.

Jenny Liu, MBA is a Digital Transformation Strategist, who started Mindracle to help executives at Life Science companies commercialize research. She help enable technology to:

- Create compelling customer experiences
- Exploit the power of core operations for competitive advantages
- Reinvent business models

With over 10 years of experience in operating and advisory roles, she worked in Management Consulting, Marketing, Sales, Operations, and Research & Development at organizations,

ranging from software startups to Fortune 500 companies, in Health Care. After consulting and mentoring for various companies in biopharma, diagnostics, and digital health, she is investing the next phase of her career in venture capital.

After graduating with a BS degree in Biology from the Massachusetts Institute of Technology (MIT) and an MBA degree with Distinction from Hult International Business School, she continues to apply what she learns. She gives back to the community as a CABS Executive Council member and an MIT Alumni Angels of Northern California Officer. As a Hakka American businesswoman, she also enjoys experimenting with culinary creations, heli-boarding in untouched powder, and dragon boat racing around the world.

Simon Cen, MS, MBA

1. Educational background

MBA, Cornell; MS, Georgia Tech, BS, Zhejiang University.

2. Company/current position

Enverest, Founder and Managing Partner

3. Work experience

About 15 years in business operations and management consulting at McKinsey San Francisco, Apple, and UPS.

4. Interests of the business areas/Specialty in life sciences

Strategy, Business Development, International Market Entry, Merger & Acquisition.

5. Any additional info you would like the mentees to know about you

Chapter Chair of CABS Singapore and China

Dr. Cheni Kwok, is a Managing Partner and Founder of Linear Dreams LLC, a management consultancy and valuation software firm specialized in corporate strategy, business/corporate development, portfolio analysis, and valuation services for the life science industry. Prior to founding Linear Dreams LLC, Dr. Kwok served as Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., where she established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, Dr. Kwok was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics. Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK). Dr. Kwok received a bachelor's degree in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, and a Ph.D. in human molecular genetics from the University of Cambridge, UK. Dr. Kwok has earned the Certified Licensing Professional (CLP) credential awarded by the Licensing Executives Society.

Jessica Sun, M.D., Ph.D is a Director of In Vivo Biology at Reset Therapeutics. She has over ten years' drug discovery and development experience in both small molecules and biologics. Her responsibility is to head in vivo screening, translational research, and biomarker development from discovery to early clinical development. In the last 20 years, she has gained experience in different disease area including renal disease, hematologic malignancy, solid tumors, inflammation disease, and recently the disorders associated with circadian rhythms. Prior to Reset, she held positions of increasing responsibilities at Threshold Pharmaceuticals and Y's Therapeutics. Jessica received her Ph.D. on Medical Sciences from Hamamatsu University School of Medicine and completed her postdoctoral training at Stanford University School of Medicine. She started her profession as a board certified practice physician and a lecturer in China Medical University and its affiliated hospital.

Dr. Sun-Hoffman is a licensed US patent attorney. She currently consults in biotech, pharmaceutical legal areas. Dr. Sun-Hoffman held positions at Life Technologies Corporation formerly Applied Biosystems as a Senior Patent Attorney and as a managing patent attorney at Celera Genomics. She obtained Celera's first patent. She is also a former United States Patent and Trademark Office (USPTO) patent examiner. She has more than 10 years of biomedical research experience including several years as a postdoctoral research fellow with several publications at National Institutes of Health (NIH) in Frederick and Bethesda, Maryland. She currently serves legal consultant for companies in US, China, Taiwan and Japan. Dr. Sun-Hoffman also drafts and negotiates contracts with various kind of the deals. She also helps company on regulatory issues in China. She has given many talks in SIPO and WIPO with USPTO delegation. She was president of Chinese Bioscience Association in 2013. Previously, she was Biotechnology Industry Organization's (BIO) Chief Advisor for Asia and president of Chinese BioPharmaceutical Association, as well as Chief Representative for China Medical City, Taizhou, Jiangsu. Currently, she serves as Vice Chair of LES International University-Industry-Government subcommittee. Dr. Sun-Hoffman has a Juris Doctor (J.D.) degree and Ph.D. degree in Biochemistry/Cell and molecular Biology. Dr. Sun-Hoffman is admitted to the Maryland Bar and she's registered to practice before the U.S. patent and Trademark Office.

Shichang Miao, Ph.D., is a past president of CABS (2009-2010). He is employed as Executive Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a public biotech company focusing on the drug discovery and development through regulation of chemokine receptors. Previously, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He holds a Ph.D. in organic chemistry / natural products chemistry from the University of British Columbia (Vancouver) and carried out postdoctoral research in organic chemistry and biochemistry. In addition to his CABS leadership activities, he is also the founder and president of Pharmaceutical & BioScience Society International (PBSS), a professional organization of 5000+ members with chapters in the San Francisco Bay Area, San Diego, Boston, Vancouver and Korea.

Shenshen Hu has 10-years research experience in the field of organic synthesis, bioinspired catalysis and green chemistry. She is currently a postdoctoral researcher in Department of Chemistry at the University of California, Berkeley, investigating the role of protein motions in biocatalysis and related design principles. Before joining UC Berkeley, She got her Ph.D. in organic chemistry from Institute of Chemistry, Chinese Academy of Science, focusing on the bioinspired design of supramolecular catalysis and organocatalysis. Shenshen also has a multidisciplinary background in patent law and business. She has been deeply involved and contributed to Berkeley Entrepreneur Community as Chair/Executive Committee member of Berkeley Postdoctoral Entrepreneurial Program. She was a patent examiner at State Intellectual Property Office of the P.R.C. for one year.

Shelly Xiong, Ph.D., RAC is currently the Vice President of Regulatory at Eiger BioPharmaceuticals, Inc. She has over 20 years of pharmaceutical industrial experiences across a broad spectrum of drug development processes. She has extensive experiences in drug discovery, clinical development, regulatory strategy, and commercial activities. Prior to Eiger BioPharmaceuticals, she held various leadership positions at InterMune (Director of Regulatory Affairs), Gilead Sciences (Associate Director of Regulatory Affairs; Principal Scientist in Clinical Virology) and Covance (Director of China Operations). She was also a co-founder and Chief

Scientific Officer of a start-up company. She received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.

Kedan Lin, Ph.D. is a Senior Scientist and Therapeutic Area Leader for Oncology Large Molecules in the Department of Pharmacokinetics & Pharmacodynamics at Genentech. She has fifteen years of discovery and development experience in both small molecules and biologics. Her group is responsible for characterizing PKPD properties for oncology large molecules and applying integrated quantitative pharmacological approach in selecting and optimizing novel therapeutics. She also leads multiple pharmacology teams for antibody drug conjugates, and her teams are responsible for overall pharmacology support from discovery to clinical development. Prior to Genentech, she held positions of increasing responsibilities at Celera Genomics and Exelixis. Kedan received her Ph.D. from University of California, San Francisco.

Dr. Jingyi Xiang has over fourteen years of experience in biomedical research, with indepth knowledge and expertise in therapeutic antibody analytics. For the past four years as Head of Bioanalytics at Eureka Therapeutics, Dr. Xiang has led a team responsible for the detailed biochemical and biophysical characterization of more than a dozen therapeutic monoclonal antibody candidates. He has also been involved with the development of novel T-cell immunotherapy targeting intracellular cancer antigens. Dr. Xiang received his B.S. in Chemistry from Peking University, Ph.D. in Biochemistry from the State University of New York at Stony Brook, and postdoctoral training at UC Berkeley.

Zheng (Jen) Liu, J.D., an of counsel in the Silicon Valley office, Orrick, is a member of the Intellectual Property Group. Ms. Liu's practice focuses on patent, trade secrets, and unfair competition litigation, intellectual property counseling, due diligence and technology transactions across a broad range of industries, including biotechnology, pharmaceutical, medical devices, Internet and telecommunications. Before joining Orrick, Ms. Liu was an associate at a prominent IP litigation boutique firm, where she was involved in matters for Amgen Inc., Angiotech Pharmaceuticals Inc., Isis Pharmaceutical Inc., Napo Pharmaceuticals, Inc., and Lilly ICOS LLC. Ms. Liu worked in anti-viral drug development at Johnson & Johnson between graduate school and law school, therefore understands the science and process of drug development as well as the business objectives of corporations. Ms. Liu was born and raised in China. She has served on the Executive Committee of the Berkeley Chinese Alumni International Association and on the board of the University of Science & Technology (USTC) Alumni Association. She was also the recent former President and current board member of Chinese Lawyers' Association in the Bay Area (CALOBA). She has been active in promoting mutually beneficial legal and business relationships between the United States and China, helping Chinese law students and junior lawyers succeed in the United States, and lecturing Chinese companies and technology associations on legal issues faced by Chinese companies or professionals. She also writes articles for Chinese language publications, such as the prestigious Caijing magazine, on issues of U.S. law. She also provides pro bono legal services for victims of domestic violence.

Ruhong Jiang, Ph.D., is cofounder and CEO of Applied StemCell, Inc. - a global leading company in gen editing and stem cell areas, located in San Francisco Bay area. He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies. Before starting Applied StemCell, Ruhong was general manager of MicuRx (Shanghai) Pharmaceutical, Inc. a California-based biopharmaceutical company where he set up its entire China operation. From 2005-2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with

multimillions of annual budget. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then project manager at Genaissance Pharmaceuticals from 2000-2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology, and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma State University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin's lab. Dr. Jiang has authored and co-authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker-based molecular assays or diagnosis, CRO service, and drug research and development.

Janet (Jian) Xiao, Ph.D., J.D., is a partner in Morrison & Foerster's Life Science Group residing in the Palo Alto office. She primarily represents clients in the biotechnology and pharmaceutical industries in their world-wide patent procurement, patent portfolio management, and strategic planning. Dr. Xiao has significant experience in developing and strengthening her clients' complex patent portfolios to maximize their commercial value and success. She advises biopharmaceutical companies such as Celgene and Genentech and research institutions such as University of California on patent matters relating to various technologies including antibody therapeutics, personalized medicine, drug delivery systems, drug screening platforms, diagnostics, and nutraceuticals. She also represents many start-up biopharmaceutical companies to help them build a strong IP position from the inception. She also prepares legal opinions on patent validity and freedom to operate, conducts IP due diligence reviews for business transactions, and is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China. She is frequently called upon to advise clients on IP issues relating to US/China cross-border transactions and operations in China, and is frequently invited to speak on IP issues both in the US and in China.

Dannis Chang, PharmD received his Bachelor of Science in Molecular and Cellular Biology from UC Berkeley. After receiving his undergraduate degree, he worked in project management at Genentech in the Translational and Molecular Oncology Division, as well as a researcher at LifeScan Inc. After several years in the workforce, he returned to school and received a doctorate of pharmacy degree from the University of Southern California School Of Pharmacy and completed a 2 year post-doctoral PharmD Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division. During his time at Novartis, he rotated through various departments such as US and Global Medical Information Services, Field Medical Operations (MSLs), Managed Markets and Payer Access, and Scientific Communications. He also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Dannis joined Genentech Inc. in May 2012 as a senior product specialist in Medical Communications for Avastin, with a focus in lung, renal cell, and gynecologic cancers. He also served as the medical science director where he functioned as the scientific lead for the cancer immunotherapy franchise within US Medical Affairs. Currently, he is the strategic program lead within Medical Affairs Business Operations, where he focuses on developing capabilities aimed at improving healthcare outcomes and helped the organization apply the latest scientific and technological advances to significant issues within the business.

Dr. Harry Liu

Current position: Safety Science Leader, Genentech
Area of mentorship: Product development, Safety Risk Management

Dr. Ee Fan Goh

Current position: Prudential, Financial Services Director. Enverest Partner
Area of mentorship: Business Development

Dr. Kai Zheng

Current position: Scientist, Genentech
Areas of mentorship: Pharmaceutical R&D, Biotechnology Development

Dr. Ceasar Ho

Current position: Principal, HGA Architects
Area of mentorship: Project management

Dr. Yen-Chi Wu

Current Position: Post-doc, Stanford
Area of mentorship: Biotechnology development, project management

Dr. Shian-Jiun Shih

Current position: Tessa Therapeutics Inc, VP, Product Development
Areas of mentorship: Leadership

Ben Wang, JD

Current Position: VP/Chief IP Counsel
Area of Mentorship: Law, business, international career

Ruimei (Linda) Li, MD, Ph.D.

Current Position: Clinical Trial Manager, Gilead
Area of Mentorship: Drug development, Clinical trials

Dr. Yann Chong Tan

Current Position: Atreca Pte Ltd, Head of Research
Area of Mentorship: Entrepreneurship

Dr. Lawrence Wee

Current Position: Chief Data Scientist at Zuellig Pharma
Area of Mentorship: Research, business development, data science, AI

Dr. Patty Kiang

Dr. Vivian Fu